mRNA-based gene editing therapeutics

Overview

mRNA-based gene editing therapeutics are a class of investigational medicines that use messenger RNA to transiently express gene-editing components in target cells. In contrast to DNA-based delivery, mRNA does not need to enter the nucleus and is not intended to integrate into the genome, which makes it attractive for applications where short-lived expression of a nuclease, base editor, or related editing machinery is sufficient to achieve a therapeutic effect. The central pharmaceutical challenge is delivery: mRNA is large, negatively charged, and inherently unstable, so it typically requires a carrier system such as lipid nanoparticles (LNPs) or related liposomal platforms.

In recent biomedical research, mRNA-based gene editing therapeutics have been discussed alongside broader mRNA delivery technologies, including ionizable lipid nanoparticles, biodegradable lipid formulations, and liposome-based platforms. These systems are being optimized to improve potency, tissue targeting, safety, and pharmacokinetics. The same delivery principles also underpin mRNA vaccines and mRNA-encoded monoclonal antibody therapies, making this field closely connected to work on COVID-19, influenza A virus, and other infectious or immune-mediated diseases.

Focus of Latest Publications

Recent publications have focused less on a single standardized gene-editing product and more on the enabling delivery technologies that would make mRNA-based gene editing therapeutics feasible in vivo. A recurring theme is that mRNA-loaded LNPs remain the dominant platform for intracellular delivery of therapeutic RNA cargo. One study on whole-body pharmacokinetics examined intravenous administration of mRNA-loaded lipid nanoparticles and tracked the ionizable lipid, the mRNA, and the expressed antibody, highlighting how formulation behavior and expression kinetics can be measured after systemic dosing. Although that work centered on antibody expression rather than editing per se, it is directly relevant to gene-editing therapeutics because the same delivery and biodistribution constraints apply to any mRNA-encoded therapeutic protein.

Several studies addressed formulation design. One report described plug-and-play assembly of biodegradable ionizable lipids for potent mRNA delivery and gene editing in vivo, explicitly framing mRNA-based gene editing therapeutics as promising but limited by suboptimal delivery platforms. Another study showed that spatial tail design in ionizable lipids can enhance the safety and efficacy of mRNA delivery, reinforcing the importance of lipid architecture in controlling transfection performance and tolerability. Related work on dual ionizable lipids, including ALC0315 and SM102 in a novel LNP formulation, showed improved in vivo delivery and time-dependent expression of messenger RNA and self-amplifying RNA, supporting the idea that formulation engineering can extend to multiple RNA modalities relevant to editing workflows.

Other studies expanded the delivery landscape beyond conventional LNPs. Oligo(ethylene glycol)-functionalized polycarbonate lipid nanoparticles were reported to attenuate PEG immunogenicity while supporting mRNA delivery, addressing a known barrier to repeated administration. A preformulated, shelf-stable, dendritic cell-targeting nanogel mRNA vaccine platform was presented as a way to reduce cold-chain dependence and improve targeting precision, which is relevant to any therapeutic mRNA platform requiring cell-selective delivery. Liposomal lipid nanoparticles containing dihydrosphingomyelin were also reported to improve stability and extend hepatic and extrahepatic transfection, again emphasizing the importance of carrier composition for tissue distribution.

Safety and translational feasibility were another major focus. A nonclinical safety study reported similar safety profiles for mRNA therapeutics containing unmodified or N1-methyl-pseudouridine-modified nucleosides after repeated administration, supporting the broader use of modified mRNA in therapeutic settings. A separate nonclinical safety evaluation of mRNA/LNP platform agents summarized evidence from comprehensive animal toxicity studies and positioned antigen-encoded mRNA in LNPs as a rapidly expanding platform extending beyond prophylactic vaccines into therapeutic applications. These findings are relevant to gene-editing therapeutics because repeated or systemic dosing may be required for some indications, and the tolerability of both the RNA cargo and the lipid carrier is critical.

The recent literature also demonstrates the breadth of therapeutic applications that share the same delivery infrastructure. HSV-2 gC2 mRNA immunization in mice used nucleoside-modified mRNA encapsulated in LNPs and showed protection by inducing antibodies that bind immune evasion epitopes. Another study delivered monoclonal antibodies using mRNA lipid nanoparticles and reported protection against SARS-CoV-2 and influenza after a single mRNA encoding both heavy and light chains was administered intravenously or intramuscularly. While these are not gene-editing studies, they show that mRNA-LNP systems can achieve biologically meaningful in vivo protein expression, which is the same foundational requirement for mRNA-based editors.

Mechanistic and analytical studies further inform the field. Mapping mRNA localization and internal structure in LNPs using solid-state dynamic nuclear polarization NMR and proton spin-diffusion modeling addressed how large single-stranded mRNA is organized within nanoparticles, a question directly relevant to release kinetics and delivery efficiency. Another study on mRNA delivery emphasized that the molecular architecture of ionizable lipids critically determines performance. Together, these works suggest that the success of mRNA-based gene editing therapeutics depends not only on the encoded editing payload but also on the physical chemistry of the carrier.

Key Publications

• NEWJun Whole-Body Pharmacokinetics of Ionizable Lipid, mRNA, and the Expressed Antibody following Intravenous Administration of mRNA-Loaded Lipid Nanoparticles. (The AAPS journal, 2026, PMID 42373925): "LNPs encapsulating mRNA were prepared via microfluidic mixing and characterized for physicochemical properties and encapsulation efficiency."
• NEWJun Calcium Overloading-Induced UBE2O Upregulation Alleviates Neuronal Apoptosis. (Molecular neurobiology, 2026, PMID 42371236): "MEF2A facilitates UBE2O promoter activity, as well as its expression at both mRNA and protein levels."
• NEWJun Design and integration of a novel bioreactor for articular cartilage tissue manufacturing with real-time feedback of chondrogenic gene expression. (Biofabrication, 2026, PMID 42276100): "This novel bioreactor provides a platform for further AC research with the ultimate design goal of generating a transfer function that maps growth factor inputs to mRNA expression outputs for real-time control."
• NEWJun Oligo(ethylene glycol)-functionalized polycarbonate lipid nanoparticles for mRNA delivery with attenuated PEG immunogenicity. (Journal of controlled release : official journal of the Controlled Release Society, 2026, PMID 42361911): "mRNA vaccines delivered by lipid nanoparticles (LNPs) have enabled clinical success in combating the COVID-19 pandemic, demonstrating LNPs as a promising nanocarrier for mRNA delivery."
• NEWJun Spatial Tail Design in Ionizable Lipids Enhances the Safety and Efficacy of mRNA Delivery. (Small methods, 2026, PMID 42359610): "Messenger RNA (mRNA) delivery critically depends on the molecular architecture of ionizable lipids within lipid nanoparticles (LNPs)."
• Jun HSV-2 gC2 mRNA immunization in mice protects by producing antibodies that bind immune evasion epitopes. (PLoS pathogens, 2026, PMID 42348550): "Mice were immunized with 0.25, 0.5, 1, 10, or 30 µg of gC2 lipid nanoparticle (LNP)-encapsulated nucleoside-modified mRNA and challenged intravaginally with HSV-2."
• Jun Mapping mRNA Localization and Internal Structure in Lipid Nanoparticles through Solid-State Dynamic Nuclear Polarization NMR and Proton Spin-Diffusion Modeling. (Small methods, 2026, PMID 42338277): "...particularly in the presence of large, single-stranded messenger RNA (mRNA), remains poorly understood."
• Jun Nonclinical Safety Profiles of mRNA Therapeutics Comprising Unmodified or N1-Methyl-Pseudouridine-Modified Nucleosides Are Similar Following Repeated Administration. (International journal of toxicology, 2026, PMID 42319297): "mRNA, either with unmodified or modified nucleosides, has become an important modality in medicines and vaccines."
• Jun Preformulated, Shelf-Stable, Dendritic Cell-Targeting Nanogel mRNA Vaccine Delivery Platform. (Bioconjugate chemistry, 2026, PMID 42225260): "Current mRNA-based vaccine platforms are limited by complex fabrication, stringent cold-chain dependence, and off-target in vivo delivery, restricting their global accessibility and targeting precision."
• Feb Delivery of monoclonal antibodies using mRNA lipid nanoparticles confers protection against SARS-CoV-2 and influenza. (Molecular therapy. Nucleic acids, 2026, PMID 41858837): "High serum concentrations of mAbs were achieved upon delivery of a single mRNA encoding both heavy and light chains via intravenous or intramuscular routes using prototypic LNP formulations."